New LC-HRMS/MS method with immunoaffinity purification detects CJC-1295 and other peptides down to 5 pg in urine
Background
Detecting the misuse of bioactive peptides in sports is a significant challenge for anti-doping authorities. This class of compounds, with molecular masses from 2-12 kDa, includes growth hormone releasing hormones like CJC-1295, synthetic insulins, synthetic ACTH, and growth factors like IGF-I. These substances can manipulate various performance-enhancing pathways but are difficult to screen for efficiently. Existing methods often target specific peptides individually. The primary challenge is the need for a single, comprehensive, high-throughput, and cost-effective analytical procedure that can simultaneously test for a broad panel of these banned substances in both blood and urine samples, which are the most common specimens in doping controls.
Study Design
Researchers developed and validated a new analytical method designed for sports drug testing. The procedure involves an initial pre-concentration of target analytes from urine or blood plasma samples using ultrafiltration. This is followed by a crucial immunoaffinity purification step using paramagnetic beads coated with antibodies. The purified peptides are then separated using nano-ultra high performance liquid chromatography (nano-UHPLC) and detected with high resolution tandem mass spectrometry (LC-HRMS/MS). The method was validated for specificity, recovery, linearity, imprecision, limit of detection, and ion suppression. Proof-of-principle was established by analyzing samples from administration studies of insulin degludec, detemir, aspart, and synacthen.
Results
The expanded test method was successfully validated and proved fit-for-purpose for detecting a wide range of performance-enhancing peptides in both urine and plasma. The method demonstrated acceptable linearity and imprecision of <25%. Analyte recovery varied significantly, ranging from 11% to 69%, depending on the specific peptide and matrix. The limits of detection (LOD) were notably sensitive, reaching levels as low as 5-100 pg in urine and 0.1-2 ng in plasma.
The analysis of administration study samples for several peptides, including insulin degludec, detemir, aspart, and synacthen, confirmed the method's practical applicability and provided essential proof-of-principle for its use in real-world anti-doping scenarios. This confirms the procedure can effectively identify the presence of these substances in biological samples after administration, a critical requirement for any doping control test.
Key Findings
- New method combines ultrafiltration, immunoaffinity purification, and LC-HRMS/MS.
- Limit of detection achieved was 5-100 pg in urine and 0.1-2 ng in plasma.
- Analyte recovery varied widely between different peptides, ranging from 11-69%.
- Method imprecision was validated to be less than 25%.
- Successfully detected insulin degludec, detemir, aspart, and synacthen in administration study samples.
Why It Matters
This new comprehensive testing protocol represents a significant upgrade for anti-doping agencies. By enabling the simultaneous screening of numerous peptides like CJC-1295, insulins, and growth factors in a single run, it increases testing throughput and reduces costs. For athletes using these compounds, the risk of detection is now higher due to the method's enhanced sensitivity and breadth. The key takeaway is that a single blood or urine test can now screen for a much wider array of peptides, making it harder to evade detection. While this is a lab methodology and not a therapeutic protocol, its implementation will directly impact the landscape of sports drug testing, making it more difficult for individuals to use these specific performance-enhancing drugs without being caught. The validation with administration samples shows it is ready for practical application.
TitrateLab articles covering CJC-1295
Written by TitrateLab, separately from the study summarized above.
